About Omeros Corporation Omeros Is A Biopharmaceutical Company Committed To Discovering, Developing And Commercializing Both Small-molecule And Protein Therapeutics For Large-market As Well As Orphan Indications Targeting Inflammation, Coagulopathies And Disorders Of The Central Nervous System.

Medical Editor: William C. Corneal incision – Two cuts are made through the clear cornea to allow insertion of instruments into the eye. January 1999. This allows fluid from other parts of the eye to rapidly enter the lens leading to swelling and then whitening, obstructing light from reaching the retina at the back of the eye. In the retrospective study, three groups of patients were evaluated: LASIK Group: Forty consecutive patients scheduled for cataract surgery who had previously undergone LASIK. Wearing sunglasses to protect from prolonged direct exposure to UV sunlight, and not smoking, may assist to prevent the early development of cataract. http://lakefeststormlake.com/samanthagomezfun/2016/11/04/options-for-vital-issues-for-retinal-detachment/Cataracts you’re born with congenital cataracts. Cataracts are the most common cause of vision loss in people over age 40 and is the principal cause of blindness in the world. In order to get a clear image onto the retina, the portions of the eye in front of the retina, including the lens, must be clear and transparent. Intraocular lenses are usually mono focal, correcting for either distance or near vision. After surgery, your need for glasses will often be reduced, but not eliminated.

The data with the PPAR-gamma agonist are encouraging and suggest that it has therapeutic potential for opioid use disorder. These clinical findings are exciting, particularly given that statistically significant improvement was seen on top of the combination of buprenorphine and naloxone, one of the most frequently prescribed treatments for heroin addiction with annual worldwide sales of in excess of $1.1 billion, stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. Heroin abuse affects over 9 million people worldwide. These clinical data, together with the recently reported discovery of the anti-craving effects and brain white matter protection in patients with cocaine use disorder, demonstrate the potential importance of OMS405 in the fight against the global addiction epidemic. http://www.nominorsindetention.org/usefuleyesurgeon/2016/11/04/finding-help-on-methods-in-glaucoma/About Omeros Corporation Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Part of its proprietary PharmacoSurgery platform, the companys first drug product, OMIDRIA (phenylephrine and ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in April 2015. OMIDRIA is the first and only FDA-approved drug (1) for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain and (2) that contains an NSAID for intraocular use. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has clinical-stage development programs focused on: complement-related thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntingtons disease and cognitive impairment; and addictive and compulsive disorders. In addition, Omeros has a proprietary G protein-coupled receptor (GPCR) platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development, and a platform used to generate antibodies. Read More Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/omeros-announces-positive-data-phase-110000476.html

Leave a Reply

Your email address will not be published. Required fields are marked *